Clinical Trial Update: Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

View source ↗

Summary

A registered clinical registry evaluating treatment satisfaction and KarXT utilization in schizophrenia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Schizophrenia | Status: RECRUITING